Skip to content
Alembic Pharmaceuticals logo

Alembic Pharmaceuticals

APLLTD NSE
₹906.70 +103.90 (+12.94%)
P/E
25.71
View as Markdown
MCP
Close 4 Nov 2026 ₹906.70 −8.65 −0.94% 1Y
Start ₹915.35

Key Fundamentals

SmallcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
12.60%
Debt to Equity
0.25
EPS (TTM)
₹35.27
Book Value
₹288.70
Market Cap
—
P/E (TTM)
25.71
P/B
3.14
ROE
13.40%
Dividend Yield
1.49%
EBITDA
₹1,173 Cr
52W High
₹963.35
52W Low
₹635.80
Day Range
₹803.65 – ₹963.35
Volume
41,62,581

Peer Comparison

Healthcare › Pharmaceuticals

Alembic Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Alembic Pharmaceuticals (this company)
₹906.7025.71₹16,169 Cr3.141.49%13.40%12.60%₹7,784 Cr₹690 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.70%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

52 Average

Data confidence 100/100

Category scores

Quality
40
Weak
Returns, margins, earnings quality 22% weight
Valuation
78
Strong
Cheap vs sector & own history 24% weight
Growth
44
Weak
Sales & profit trajectory 9% weight
Financial Health
35
Poor
Solvency, leverage, coverage 9% weight
Momentum
52
Average
Trend strength, vol-adjusted 12% weight
Ownership
48
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 35.7%

Weaknesses

5
  • Stock is trading at 2.73 times its book value
  • The company has delivered a poor sales growth of 6.37% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 12.7% over last 3 years.
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3412
OscillatorsBearish342
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
76.25
Bearish
MACD (12,26,9)
2.42
Bullish
SMA (50)
815.62
Bullish
SMA (200)
778.16
Bullish

As of

Analyst Rating

Based on 8 analysts
TIED50%

4 of 8 analysts rate Buy, 4 Hold, 0 Sell.

As of

BUY
4
50%
HOLD
4
50%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+8.78%
5Y+6.37%
3Y+9.12%
1Y+10.09%
TTM+14.10%

Net profit

Net profit growth by window
10Y−0.70%
5Y−10.15%
3Y+25.19%
1Y+15.29%
TTM+14.62%

Operating cash flow

Operating cash flow growth by window
10Y−1.89%
5Y−11.75%
3Y+2.65%
1Y+789.77%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−16.55 pp
5Y−12.18 pp
3Y+3.20 pp
1Y+0.15 pp
TTM−0.40 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹3,105 Cr
Mar 2018₹3,131 Cr
Mar 2019₹3,935 Cr
Mar 2020₹4,606 Cr
Mar 2021₹5,393 Cr
Mar 2022₹5,306 Cr
Mar 2023₹5,653 Cr
Mar 2024₹6,229 Cr
Mar 2025₹6,672 Cr
Mar 2026₹7,345 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹403 Cr
Mar 2018₹413 Cr
Mar 2019₹583 Cr
Mar 2020₹801 Cr
Mar 2021₹1,146 Cr
Mar 2022₹521 Cr
Mar 2023₹342 Cr
Mar 2024₹616 Cr
Mar 2025₹582 Cr
Mar 2026₹671 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹377 Cr +8.5% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk medium

Alembic Pharmaceuticals trades at ₹906.7 as of 2026-11-04 with a market cap of ₹16,169 crore and a P/E (TTM) of 25.71. The company shows recent profit momentum with 26% TTM profit growth and 14% TTM sales growth, but longer-term returns have been uneven, with 5-year compounded profit growth at -9% and stock CAGR of -1% over five years.

Bull Case 8
  • TTM profit growth of 26% signals a strong earnings recovery after years of subdued performance
  • TTM sales growth of 14% marks a notable acceleration from the 5-year compounded sales growth of just 6%
  • Debt-to-equity ratio of 0.25 indicates a conservatively leveraged balance sheet, limiting financial risk
  • Healthy dividend payout ratio of 35.7% with a current dividend yield of 1.49%, providing tangible shareholder returns
  • 3-year compounded profit growth of 28% suggests the earnings recovery is not just a single-quarter phenomenon
  • 10-year compounded sales growth of 9% demonstrates the company has sustained top-line expansion over a long period
  • Stock is trading roughly 6% below its 52-week high of ₹963.35, indicating relative price resilience near recent highs
  • ROCE of 12.77% remains above the cost of debt implied by the low leverage, suggesting the business generates adequate returns on deployed capital
Bear Case 8
  • 5-year compounded profit growth of -9% reflects a prolonged period of earnings decline before the recent recovery
  • ROE of 11.83% is modest, and the 3-year average ROE of 13% remains below the 10-year average of 16%, indicating a structural dip in return efficiency
  • 5-year stock CAGR of -1% shows the market has not rewarded shareholders over a meaningful investment horizon
  • P/E (TTM) of 25.71 is elevated relative to the 5-year compounded sales growth of only 6%, raising questions about valuation sustainability
  • Price-to-book ratio of 3.14 implies a premium valuation that demands continued earnings acceleration to be justified
  • 5-year compounded sales growth of 6% lags the 10-year rate of 9%, suggesting a deceleration in top-line momentum over the medium term
  • Potential capitalisation of interest costs could overstate reported profitability and asset values
  • An apparently low tax rate introduces uncertainty about the sustainability of bottom-line figures if effective tax rates normalise

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Alembic Pharmaceuticals is steadily building out its US generics pipeline, adding a new USFDA approval (246 total ANDAs) and signing a meaningful complex generics collaboration targeting a $5 billion reference market. International expansion continues with a new UAE subsidiary. No notable headwinds emerged in this period. The trend is constructive, with FY28 product launches from the DifGen partnership as the next key catalyst to watch.

Positives 2
  • USFDA nod for otic suspension Oct 17

    Received final USFDA approval for Ciprofloxacin and Dexamethasone Otic Suspension targeting a $110 million US market. Total ANDA approvals now stand at 246.

  • DifGen deal expands US generics Nov 4

    Expanded collaboration with DifGen targets a ~$5 billion US reference market with 20+ differentiated complex generic products. Initial product launches expected from FY28, with Alembic handling US commercialization.

Neutral 2
  • UAE subsidiary incorporated Oct 19

    Incorporated Alvesta Pharmaceuticals FZCO in Dubai via a wholly owned subsidiary to distribute pharmaceutical products in the UAE market.

  • KMP contact details updated Nov 4

    Board approved updated contact details for Key Managerial Personnel for SEBI Reg 30(5) disclosure compliance on November 4, 2026.

Quarterly Results

₹ Cr
APLLTD quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,486
1,595
1,631
1,517
1,562
1,648
1,693
1,770
1,711
1,910
1,876
1,848
2,150
Expenses
1,287
1,387
1,364
1,257
1,325
1,409
1,433
1,498
1,430
1,594
1,585
1,620
1,818
Operating Profit
199
208
266
260
237
239
260
271
281
316
292
228
332
OPM %
13%
13%
16%
17%
15%
15%
15%
15%
16%
17%
16%
12%
15%
Other Income
12
10
3
4
2
30
10
14
6
6.91
−27
2
15
Interest
14
16
15
11
13
19
22
25
24
24
23
23
28
Depreciation
66
68
69
69
69
71
70
69
74
76
80
89
98
PBT
130
135
185
183
157
180
177
193
190
224
162
119
221
Tax %
7%
−1%
2%
3%
14%
15%
23%
18%
19%
18%
18%
−70%
22%
Net Profit
121
137
180
178
135
153
138
157
154
184
132
202
172
EPS (₹)
6.14
6.95
9.18
9.07
6.85
7.8
7.04
7.98
7.85
9.4
6.76
10.31
8.8

Profit & Loss

₹ Cr
APLLTD profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
2,056
3,166
3,105
3,131
3,935
4,606
5,393
5,306
5,653
6,229
6,672
7,345
7,784
Expenses
1,653
2,159
2,490
2,488
3,061
3,383
3,913
4,432
4,970
5,296
5,664
6,224
6,617
Operating Profit
403
1,007
615
643
874
1,223
1,480
874
682
932
1,008
1,121
1,167
OPM %
20%
32%
20%
21%
22%
27%
27%
16%
12%
15%
15%
15%
15%
Other Income
4
7
2
7
9
−39
87
56
−2
28
56
−14
−1
Interest
4
5
5
3
18
27
16
18
50
56
79
94
98
Depreciation
44
72
83
105
115
157
183
287
275
273
279
319
342
PBT
359
936
529
541
749
1,000
1,368
625
355
632
706
694
726
Tax %
21%
23%
23%
22%
21%
20%
19%
17%
4%
3%
18%
3%
—
Net Profit
283
720
403
413
583
801
1,146
521
342
616
582
671
690
EPS (₹)
15.01
38.2
21.39
21.89
31
43.97
58.33
26.5
17.4
31.33
29.68
34.33
35.27
Div. Payout %
23%
9%
19%
18%
18%
23%
24%
38%
46%
35%
37%
35%
—

Balance Sheet

₹ Cr
APLLTD balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
38
38
38
38
38
38
39
39
39
39
39
39
Reserves
847
1,560
1,865
2,182
2,681
3,182
5,028
5,198
4,331
4,779
5,152
5,636
Borrowings
264
114
89
708
1,128
1,747
584
717
722
513
1,258
1,430
Other Liabilities
493
718
698
1,013
931
1,022
1,058
1,167
1,090
1,114
1,325
1,658
Total Liabilities
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
8,763
Fixed Assets
547
708
799
993
1,158
1,552
1,788
1,798
2,398
2,547
2,524
3,081
CWIP
83
93
396
1,010
1,551
1,846
2,183
2,304
601
524
837
683
Investments
2
87
50
42
49
18
236
118
96
93
127
141
Other Assets
1,009
1,541
1,444
1,896
2,019
2,573
2,502
2,902
3,087
3,281
4,285
4,858
Total Assets
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
8,763

Cash Flow

₹ Cr
APLLTD cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
172
948
329
312
812
449
1,463
552
724
803
88
783
Investing
−256
−307
−486
−884
−756
−731
−840
−372
−448
−321
−568
−506
Financing
87
−224
−129
503
59
155
−597
−217
−262
−438
444
−164
Net Cash Flow
3
417
−286
−69
115
−127
26
−37
14
45
−37
113
Free Cash Flow
−52
647
348
−495
49
−285
804
128
282
487
−466
290
CFO/EBITDA
60
114
73
70
112
56
115
77
115
88
16
79

Ratios

APLLTD financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
64
40
40
61
45
69
24
56
68
60
77
73
Inventory Days
196
266
269
302
356
417
431
406
315
350
466
462
Days Payable
166
264
213
313
237
220
194
178
145
157
179
154
Cash Conversion Cycle
94
42
96
51
164
266
261
283
237
253
363
381
Working Capital Days
32
36
61
69
24
50
73
74
77
88
87
87
ROCE %
38%
66%
29%
22%
23%
24%
26%
11%
7%
13%
13%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Alembic Pharmaceuticals insights

71 extracted metrics across FY12–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 69.87%
  • DIIs 15.43%
  • Public 7.00%
  • FIIs 4.55%
  • Others 3.15%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Alembic Pharmaceuticals

What does Alembic Pharmaceuticals Ltd do?
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.
Where is Alembic Pharmaceuticals Ltd (APLLTD) listed?
Alembic Pharmaceuticals Ltd trades as APLLTD on the NSE and under code 533573 on the BSE.
Which sector does Alembic Pharmaceuticals Ltd belong to?
Alembic Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd trades at a PE ratio of 25.71 as of 4 Nov 2026, on earnings per share of ₹35.27, against a book value of ₹288.7 per share.
What is the 52-week high and low of Alembic Pharmaceuticals Ltd?
Over the last 52 weeks Alembic Pharmaceuticals Ltd has traded between ₹635.8 and ₹963.35 as of 4 Nov 2026.
Does Alembic Pharmaceuticals Ltd pay dividends?
Alembic Pharmaceuticals Ltd has a dividend yield of 1.49%.
What is the Return on Equity (ROE) of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd reported a return on equity of 13.40%. Its debt-to-equity ratio is 0.25.

Company Information

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.

Website alembic-india.com
CEO Mr. Chirayu Ramanbhai Amin
Employees 16,571
Listed 20 Sep 2011
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/APLLTD.md for Alembic Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month